NOVOZYMES ASNOVOZYMES ASNOVOZYMES AS

NOVOZYMES AS

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪26.03 B‬EUR
‪405.55 M‬EUR
‪2.40 B‬EUR
‪349.68 M‬
Beta (1Y)
0.25

About NOVONESIS (NOVOZYMES) A/S B

CEO
Ester Baiget
Headquarters
Lyngby
Employees (FY)
‪6.76 K‬
ISIN
DK0060336014
FIGI
BBG00KDZJQK3
Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of NZYM is 56.38 EUR — it has increased by 0.57% in the past 24 hours. Watch NOVOZYMES AS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange NOVOZYMES AS stocks are traded under the ticker NZYM.
NOVOZYMES AS is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
NZYM stock is 0.57% volatile and has beta coefficient of 0.25. Track NOVOZYMES AS stock price on the chart and check out the list of the most volatile stocks — is NOVOZYMES AS there?
NZYM earnings for the last quarter are 0.49 EUR per share, whereas the estimation was 0.52 EUR resulting in a −6.56% surprise. The estimated earnings for the next quarter are 0.58 EUR per share. See more details about NOVOZYMES AS earnings.
NOVOZYMES AS revenue for the last quarter amounts to ‪963.60 M‬ EUR despite the estimated figure of ‪992.33 M‬ EUR. In the next quarter revenue is expected to reach ‪961.47 M‬ EUR.
Yes, you can track NOVOZYMES AS financials in yearly and quarterly reports right on TradingView.
NZYM stock has risen by 9.52% compared to the previous week, the month change is a 8.67% rise, over the last year NOVOZYMES AS has showed a 20.09% increase.
NZYM net income for the last quarter is ‪93.61 M‬ EUR, while the quarter before that showed ‪125.20 M‬ EUR of net income which accounts for −25.23% change. Track more NOVOZYMES AS financial stats to get the full picture.
Today NOVOZYMES AS has the market capitalization of ‪26.03 B‬, it has increased by 5.59% over the last week.
NOVOZYMES AS dividend yield was 1.67% in 2023, and payout ratio reached 56.80%. The year before the numbers were 1.71% and 45.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, NZYM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVOZYMES AS stock right from TradingView charts — choose your broker and connect to your account.
NZYM reached its all-time high on Jan 3, 2022 with the price of 72.76 EUR, and its all-time low was 35.86 EUR and was reached on Jan 25, 2019. View more price dynamics on NZYM chart.
See other stocks reaching their highest and lowest prices.
As of May 9, 2024, the company has ‪6.76 K‬ employees. See our rating of the largest employees — is NOVOZYMES AS on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVOZYMES AS technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVOZYMES AS stock shows the strong buy signal. See more of NOVOZYMES AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NOVOZYMES AS future price: according to them, NZYM price has a max estimate of 66.99 EUR and a min estimate of 46.89 EUR. Watch NZYM chart and read a more detailed NOVOZYMES AS stock forecast: see what analysts think of NOVOZYMES AS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVOZYMES AS EBITDA is ‪782.40 M‬ EUR, and current EBITDA margin is 32.72%. See more stats in NOVOZYMES AS financial statements.